Pharmacist's Role in the Management of Acute Stroke

A presentation for HealthTrust Members April 22, 2021

Patrick Pauls, PharmD, BCPS PGY2 Pharmacy Resident Rutgers, The State College of New Jersey Robert Wood Johnson University Hospital Preceptor: Patrick J Bridgeman, PharmD, BCPS; Clinical Assistant Professor of Pharmacy Practice



Conflict Disclosure Statements

- Patrick Pauls There are no relevant financial interest to disclose for myself or my spouse/partner from within the last 12 months
- Patrick J Bridgeman There are no relevant financial interest to disclose for myself or my spouse/partner from within the last 12 months
- This program may contain the mention of drugs or brands presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any supplier, brand, or drug.

Learning Objectives

- 1. Define the benefits of having a pharmacist as care providers for stroke patients
- 2. Identify roles and responsibilities of the pharmacist when assisting the team in the management of an acute ischemic or hemorrhagic stroke
- 3. Formulate a plan for management and monitoring of a patient presenting with an acute ischemic stroke

Epidemiology and Impact of Stroke


- 5th leading cause of death in US
 - 2nd leading cause world-wide
- A stroke occurs every 40 seconds in the US
- Death every 4 minutes
- Leading cause of serious long-term disability
- Stroke related costs ~\$46 billion between 2014 and 2015



Definitions


<u>Stroke</u> - interruption or reduction of blood flow to the brain causing tissue necrosis from lack of oxygen and glucose

Ischemic stroke



A clot blocks blood flow to an area of the brain

Hemorrhagic stroke



Bleeding occurs inside or around brain tissue

<u>Transient ischemic attack (TIA)</u> - form of ischemic stroke where the blood flow is temporarily blocked/reduced without tissue necrosis

Sources: CDC.gov. 2021. Accessed 3/30/21 Stroke.org. AHA. 2021. Accessed 3/30/21

Balance Arms Speech Time Eyes Face



Does the person have a sudden loss of balance?

Has the

person lost vision in one or both eyes?



Does the person's face look uneven?



Is one arm weak or numb?

Is the person's speech slurred? Does the person have trouble speaking or seem confused?



Call 9-1-1 now!

Source: https://www.dukehealth.org/blog/know-signs-of-stroke-be-fast. Accessed 3/30/21

Management of Ischemic Stroke

Goals of Therapy

- Improve neurological outcome
- Reduce mortality
- Prevent recurrence
- Prevent complications

Benefits of Pharmacists in Management of Stroke

- Emergency Department (ED)
- Inpatient Setting
- Outpatient Setting
 - Ambulatory Care
 - Community Pharmacy

• Emergency Department (ED)

 Adding pharmacist to stroke pager and participation in assessment, dose verification, and patient education

Sources: Basaraba JE, et al. *Can J Neurol Sci.* 2018; 45(1):49-55. Lee E. *P T.* 2011; 36(3):159-161. Ferguson K, et al. *Crit Care Med.* 2019;47(1):656.

• Emergency Department (ED)

 Adding pharmacist to stroke pager and participation in assessment, dose verification, and patient education

Resulted in a **reduction of decision-to-needle times for thrombolytic therapy**

- Zero minute decision-to-needle: 0% to 78%

Sources: Basaraba JE, et al. Can J Neurol Sci. 2018; 45(1):49-55. Lee E. P T. 2011; 36(3):159-161. Ferguson K, et al. Crit Care Med. 2019;47(1):656.

• Inpatient Setting

- Medication reconciliation
- Participation in stroke team rounds
- Communication with community pharmacy and primary care provider (PCP)

● Inpatient Setting → **increased**:

- Identification of drug therapy problems
- Patient follow-up 4 weeks post discharge
- Medication adherence 3 months post discharge
- Adherence to stroke guideline performance indicators
- Patient satisfaction with educational sessions

- Outpatient Setting
 - Ambulatory Care
 - Stroke prevention/bridge clinic
 - Prescriptive authority/collaborative practice agreement
 - Community Pharmacy
 - Medication reviews and education
 - Resolved drug therapy problems

- Outpatient Setting
 - Ambulatory Care
 - **Reduced readmission rates** $(14.5\% \rightarrow 2.2\%)$
 - Significantly more patients reached goal:
 - Blood pressure (83% vs. 40%)
 - Lipid levels (40% vs. 13%)
 - Glucose levels (75% vs 50%)
 - Community Pharmacy
 - Prevented reduction in HRQoL scores post-stroke
 - Reduced days to pickup of antihypertensives (11 vs. 2 days)

Assessment Question 1

Which of the following is <u>not</u> a benefit of having a pharmacist involved in the management of a stroke?


- a. Improved medication adherence
- b. Reduced decision-to-needle time for thrombolysis
- c. Reduced readmission rates
- d. Reduced treatment costs

Assessment Question 1 Response

Which of the following is <u>not</u> a benefit of having a pharmacist involved in the management of a stroke?

- a. Improved medication adherence
- b. Reduced decision-to-needle time for thrombolysis
- c. Reduced readmission rates
- d. Reduced treatment costs

Get With The Guidelines[®] - Stroke Achievement Measures



 $Source: \ https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/ \ get-with-the-guidelines-stroke-recognition-criteria. \ Accessed \ 3/31/21$

Patient Case

JM is a 45 year old male who was brought in by his wife because he was feeling dizzy, slurring his words, and was having left sided weakness in his arms and legs

Management of Acute Ischemic Stroke

ED Management of Ischemic Stroke



Blood Pressure Management for Ischemic Stroke

Thrombolysis

BLOOD PRESSURE GOALS:

Before thrombolysis	During & after thrombolysis	
SBP ≤ 185 mmHg	SBP ≤ 180 mmHg	
DBP ≤ 110 mmHg	DBP ≤ 105 mmHg	


No Thrombolysis

Not eligible if SBP > 220 mmHg -OR-DBP > 120 mmHg

- Allow permissive hypertension
- Goal = 15% reduction in SBP over 24 hours

1st Line Options to Treat HTN Prior to tPA	
Drug	Dosing
Labetalol	10-20 mg IV push over 1-2 min; may repeat x 1 dose
Nicardipine	5 mg/h IV infusion; Titrate by 2.5 mg/h q5-15mins, max 15 mg/h
Clevidipine	1-2 mg/h IV; double dose q2-5mins, max 21 mg/h

Thrombolysis: Tissue Plasminogen Activator (tPA)



Source: https://ivcnorthwest.com/treatment/catheter-directed-thrombolysis-thrombectomy/. Accessed 3/30/21

Summary of Thrombolysis Clinical Data

1. Time is brain! \rightarrow goal door-to-needle time < 1 hour

2. tPA improves neurological outcomes, not mortality

3. 4.5-9 hour window not recommended

Sources: Marler JR, et al. *N Engl J Med.* 1995; 333(24):1581-7. Hacke W, et al. *N Engl J Med.* 2008; 359:1317-1329 Ma H, et al. *N Engl J Med.* 2018; 380:1795-1803

Blood Glucose

Hypoglycemia (BG < 60 mg/dL) should be corrected **prior** to use of tPA

- Hypoglycemia could mimic a stroke
- Goal BG 140-180 mg/dL

Hemorrhagic Stroke

Management of Hemorrhagic Stroke

- Anticoagulant reversal agents
- Blood pressure control

Management of Hemorrhagic Stroke

Anticoagulant reversal if currently taking:



4F-PCC = four-factor prothrombin complex concentrate, DOAC = direct oral anticoagulant, FFP = fresh frozen plasma

Source: Hemphill JC, et al. AHA. 2015;46:2032-2060

Management of Hemorrhagic Stroke

Blood pressure control

Initial SBP	Goal SBP
SBP 150-220 mmHg	< 140
SBP > 220 mmHg	Consider aggressive reduction of BP

Source: Hemphill JC, et al. AHA. 2015;46:2032–2060

Roles and Responsibilities of the Pharmacist in Acute Stroke:

Evaluating Appropriateness of Thrombolysis

Indications for Thrombolysis with tPA

- Age \geq 18 years
- Last known normal < 4.5 hours
- Diagnosis of acute ischemic stroke w/neurological deficits

Contraindications for tPA

- Severe head trauma or prior stroke in the previous 3 months
- Symptoms suggest subarachnoid hemorrhage
- Previous ICH
- Recent intracranial or spinal surgery in previous 3 months
- Intracerebral neoplasm
- Infective endocarditis
- Aortic arch dissection
- Elevated blood pressure (SBP > 185 mmHg or DBP > 110 mmHg) that cannot be lowered safely
- Active internal bleeding
- Acute bleeding diathesis (PLT < 100, heparin within previous 24 hours, warfarin w/INR > 1.7, DOAC)
- CT demonstrates infarction > one-third of cerebral hemisphere
- CT demonstrates acute ICH


Relative Contraindications for tPA

- Mild and non-disabling or rapidly improving stroke symptoms
- Very severe neurologic deficits (NIHSS score > 25) within 3 to 4.5 hour window
- Pregnancy
- Seizure at onset
- Recent major surgery or serious trauma within previous 14 days
- Recent gastrointestinal or urinary tract hemorrhage within previous 21 days
- Ischemic stroke within previous 3 months
- Recent ST-elevation acute MI within previous 3 months
- Blood glucose concentration < 50 mg/dL

Roles and Responsibilities of the Pharmacist in Acute Stroke:

Evaluating Appropriateness of Reversal

Indications for Anticoagulant Reversal in ICH



Sources: [Andexanet alfa]. Alexion Pharmaceuticals Inc. 2021. [Prothrombin Complex Concentrate (Human)]. CSL Behring. 2020.

Contraindications for Anticoagulant Reversal in ICH



HIT = heparin-induced thrombocytopenia

Sources: [Andexanet alfa]. Alexion Pharmaceuticals Inc. 2021. [Prothrombin Complex Concentrate (Human)]. CSL Behring. 2020.

Roles and Responsibilities of the Pharmacist in Acute Stroke:

Order Entry/Verification of Thrombolysis or Reversal Agent

tPA Dosing

Alteplase 0.9 mg/kg (max dose of 90 mg)

Administered over 1 hour:
Bolus: 10% over 1 minute
Infusion: The rest over the following 59 minutes

Tenecteplase 0.25 mg/kg (max dose of 25 mg)

Administered IV push over 5 seconds

Source: Powers WJ, et al. ACC. 2019; 50:e344-e418.

Reversal Dosing: 4F-PCC

Warfarin →	Pre-treatment INR	2 to < 4	4 to 6	> 6
	Dose (units Factor IX/kg)	25	35	50
	Max dose (units Factor IX)	2500	3500	5000
	Fixed dose (units Factor IX)	1500-2000		

$DOAC \rightarrow 50 \text{ mg/kg} \text{ (max of 5000 units Factor IX)}$

Sources: [Prothrombin Complex Concentrate (Human)]. CSL Behring. 2020. Tellor KB, et al. *Blood Transfus*. 2018;16(4):382-386.

Reversal Dosing: Andexanet alfa

DOAC	Last Dose	< 8 hours or unknown	≥ 8 hours
Anivohon	≤ 5 mg	Low dose	
Аріхарап	Apixaban > 5 mg/unknown High dose		Low doop
Rivaroxaban	≤ 10 mg	Low dose	Low dose
	> 10 mg/unknown	High dose	

Source: [Andexanet alfa]. Alexion Pharmaceuticals Inc. 2021.

Reversal Dosing: Andexanet alfa

Source:

DOAC	Last Dose	< 8 ho unkn		≥ 8	hours	
Apixaban	≤ 5 mg	Low o	lose			
	> 5 mg/unknowr	High dose		1 cu	, de se	
Rivaroxaban	≤ 10 mg	Low o	lose	Low dose		
	> 10 mg/unknow	n High (dose			
			Initial I	V Bolus	Follow-On I	V Infusion
[Andexanet alfa]. Alexion Pharmaceuticals Inc. 2021.		Low dose	400 mg at target rate 30 mg/min		4 mg/min for up to 120 minutes (480 mg)	
		High dose			8 mg/min for minutes (9	

Roles and Responsibilities of the Pharmacist in Acute Stroke:

Patient Education for Thrombolysis

Patient Education for Thrombolysis

- What tPA is and when it is used
- Who qualifies for tPA
- Risks and benefits of tPA
- What to monitor for and report to team
- Follow-up care and prescription counseling

Roles and Responsibilities of the Pharmacist in Acute Stroke:

Preparation of tPA

Alteplase Preparation



Wipe the top of each bottle with alcohol cotton to reduce the risk of contamination.

Place the piercing pin in the middle of the plug on the sterile diluent water vial.

Hold the double-sided piercing pin by the wings to allow it to fully enter.

Source: https://www.researchgate.net/figure/tPA-preparation-steps-and-details-Turkish-Journal-of-Cerebrovascular-Diseases-2020_fig1_ 341096225. Accessed 3/30/21

Alteplase Preparation



Place the rt-PA vial upside down on the piercing pin on the sterile water vial.



While holding both vials carefully, move the rt-PA vial slowly down.




While in this state, wait until all the water in the sterile water vial is drained.



Throw the double-sided piercing pin into the cutter piercing medical waste bin.

Source: https://www.researchgate.net/figure/tPA-preparation-steps-and-details-Turkish-Journal-of-Cerebrovascular-Diseases-2020_fig1_ 341096225. Accessed 3/30/21

Tenecteplase Preparation



Roles and Responsibilities of the Pharmacist in Acute Stroke:

Monitoring Post-Thrombolysis/Reversal

Post-Thrombolysis Monitoring

01	BP and Neuro	 Every 15 minutes x 2 hours Every 30 minutes x 5 hours Every 1 hour x 24 hours
02	Bleeding	 Hold antiplatelets/anticoagulants x 24 hrs Signs or symptoms of bleeding Concerns for ICH → hold tPA + CT head
03	Angioedema	Discontinue tPATreat similar to anaphylaxis

Sources: Powers WJ, et al. *ACC*. 2019; 50:e344–e418. Alteplase [package insert]. Genentech, Inc. 2015. Tenecteplase recombinant [package insert]. Hoffmann-La Roche Limited. 2018.

Post-Reversal Monitoring

- Clinical response
- Signs of thromboembolism
- Signs of hypersensitivity
- 4F-PCC for warfarin \rightarrow INR (baseline and 30 minutes after)

Sources: [Andexanet alfa]. Alexion Pharmaceuticals Inc. 2021. [Prothrombin Complex Concentrate (Human)]. CSL Behring. 2020.

Assessment Question 2

Which of the following is <u>not</u> a task that the pharmacist could assist with in the setting of an acute stroke?

- a. Preparation of tPA
- b. Identifying need for reversal of anticoagulants
- c. Consenting patient for thrombolysis
- d. Order entry and/or verification
- e. Ensuring patient meets inclusion and exclusion criteria

Assessment Question 2 Response

Which of the following is <u>not</u> a task that the pharmacist could assist with in the setting of an acute stroke?

- a. Preparation of tPA
- b. Identifying need for reversal of anticoagulants
- c. Consenting patient for thrombolysis
- d. Order entry and/or verification
- e. Ensuring patient meets inclusion and exclusion criteria

Pharmacist Involvement/Impact at RWJUH

Responsibilities:

- Respond to all code strokes
- Evaluate patients and review medications
- Identify contraindications to tPA/reversal agents
- Prepare and deliver tPA/reversal agents
- Monitoring BP and toxicities

Impacts:

- Patient safety: contraindications and appropriate dosing
- Improved Get With The Guidelines® stroke criteria
 - Door-to-needle time

Back to JM

JM is a 45 year old male who was brought in by his wife because he was feeling dizzy, slurring his words, and was having left sided weakness in his arms and legs

- PMH: hypertension and type II diabetes
- Last known normal was 15 minutes ago
- Medications: Lisinopril 20 mg daily, metformin 1000 mg BID
- Vitals: BP 194/100, HR 104, RR 18, Glucose 135 mg/dL, Weight 87 kg

JM is evaluated quickly before being taken to obtain a head CT

Assessment Question 3

The neurologist orders tPA for JM. Which of the following would be appropriate interventions for the pharmacist? Select all that apply

- a. Review medication list for anticoagulants
- b. Preparation of tPA
- c. Administration of alteplase bolus
- d. Preparation of 4F-PCC
- e. Ensure appropriate dosing of tPA
- f. Ensuring BP at goal before starting tPA

Assessment Question 3 Response

The neurologist orders tPA for JM. Which of the following would be appropriate interventions for the pharmacist? Select all that apply

- a. Review medication list for anticoagulants
- b. Preparation of tPA
- c. Administration of alteplase bolus
- d. Preparation of 4F-PCC
- e. Ensure appropriate dosing of tPA
- f. Ensuring BP at goal before starting tPA

Summary

- There are several benefits of having a pharmacist as care providers for stroke patients across several different care locations
- Pharmacists play a vital role in the management of an acute ischemic or hemorrhagic stroke
 - Ensuring appropriateness of therapy
 - Improving door-to-needle times
 - Rapid preparation of tPA/reversal agents

Sources: Basaraba JE, et al. Can J Neurol Sci. 2018; 45(1):49-55.; 45(1):49-55. Lee E. P T. 2011; 36(3):159-161. Ferguson K, et al. Crit Care Med. 2019;47(1):656.. 2019;47(1):656.

References

- 1. AHA. About Stroke. 2021. Stroke.org. Accessed 3/30/21
- 2. Alteplase [package insert]. South San Francisco, CA: Genentech, Inc.; 2015.
- 3. Andexanet alfa [package insert]. South San Francisco, CA: Portola Pharmaceuticals, Inc.; 2021.
- 4. Basaraba JE, Picard M, George-Phillips K, Mysak T. Pharmacists as Care Providers for Stroke Patients: A Systematic Review. *Can J Neurol Sci.* 2018 Jan;45(1):49-55. doi: 10.1017/cjn.2017.233. Epub 2017 Sep 20. PMID: 28929979.
- 5. CDC. Stroke. 2021. https://www.cdc.gov/stroke/facts.htm. Accessed 3/30/21
- 6. Ferguson K, Wilson J, Gendron B, et al. 1359: OPTIMIZATION OF THE PHARMACIST ROLE FOR THROMBOLYTIC THERAPY IN INPATIENT CODE STROKE. *Crit Care Med.* 2019;47(1):656. doi:10.1097/01.ccm.0000552103.32713.8e.
- 7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med. 2008
- 8. Hemphill JC, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. AHA. 2015;46:2032–2060.
- 9. Lee EH. American society of health-system pharmacists. P T. 2011;36(3):159-161.
- 10. Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. *N Engl J Med.* 2019; 380:1795-1803. DOI: 10.1056/NEJMoa1813046
- 11. Marler JR, et al. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med.* 1995. doi: 10.1056/NEJM199512143332401.
- 12. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2019;50:e344–e418 doi: 10.1161/STR.00000000000211.
- 13. Prothrombin Complex Concentrate (Human) [package insert]. Marburg, Germany: CSL Behring; 2020.
- 14. Rech MA, Bennett S, Donahey E. Pharmacist Participation in Acute Ischemic Stroke Decreases Door-to-Needle Time to Recombinant Tissue Plasminogen Activator. *Annals of Pharmacotherapy*, 2017; 51(12):1084 doi: 10.1177/1060028017724804
- 15. Tellor KB, Barasch NS, Lee BM. Clinical experience reversing factor Xa inhibitors with four-factor prothrombin complex concentrate in a community hospital. *Blood Transfus.* 2018. doi: 10.2450/2017.0219-16
- 16. Tenecteplase recombinant [package insert]. Mississauga, Ontario: Hoffmann-La Roche Limited; 2018.
- 17. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020;76:594-622.

Thank You for Listening Patrick Pauls pp806@pharmacy.rutgers.edu